Home>Topics>Companies>Johnson & Johnson

Johnson & Johnson JNJ

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Coloplast Moves Toward Settlement of Vaginal Mesh Cases

      Commentary

      Mon, 20 Apr 2015

      resolution. Fortunately for Coloplast, the firm's exposure to liability is limited, especially compared with Johnson & Johnson , Endo Pharmaceuticals, and Boston Scientific. The firm settled 400 of the cases for $16 million, or roughly

    2. Dividend Stock Holdings

      Commentary

      Sat, 18 Apr 2015

      in the CEF forum and has worked for me in the past. My current holdings are as follows: APU AAPL BAX KO EPD XOM GE GIS JNJ KMI MMP MA MSFT NSRGY* NVS* PFE PM PAGP PG SO SEP SBUX VZ DIS WFC GWW

    3. BRIEF-Genmab reach $10 mln milestone in Johnson & Johnson collaboration

      Headlines

      Thu, 16 Apr 2015

      * Says achieves 10 million dollar milestone in daratumumab collaboration with Janssen, a pharmaceutical company of Johnson & Johnson

    4. Friday Five: Banks Start Earnings Season Without a Bang

      Video Reports

      Thu, 16 Apr 2015

      Big pharma firm [TICKER: JNJ ] Johnson & Johnson also reported. They had a steady ..... are really driving [TICKER: JNJ ] Johnson & Johnson 's performance. The consumer ..... online in a few years, and J & J 's late-stage pipeline is

      J J found at 2:03

      drive earnings, even in this low interest rate environment. Stipp: Big pharma firm [TICKER: JNJ ] Johnson & Johnson also reported. They had a steady quarter, but not perhaps without any bumps at all. Glaser: Our analyst Damien Conover described it as steady. It was driven by the drug business; pharmaceuticals are really driving [TICKER: JNJ ] Johnson & Johnson's performance. The consumer group did OK, and the device business continued to struggle. Damien thinks these basic trends are going to continue in the years to come, but drugs are going to slow down. Some generic competition is coming online in a few years, and J & J's late-stage pipeline is not incredibly strong; there aren't a lot of drugs waiting in the wings to take over some of that
    5. S&P Advances, Driven by Energy Sector & Solid Earnings

      Commentary

      Tue, 14 Apr 2015

      stronger, while its market share was growing. Shares rose 1.90% to $63.25 on Tuesday. Health-care giant Johnson & Johnson topped Wall Street estimates with its adjusted per-share profit of $1.56 for the first quarter, while revenue

    6. J & J's first-qtr profit falls 8.6 pct

      Headlines

      Tue, 14 Apr 2015

      April 14 (Reuters) - Johnson & Johnson reported an 8.6 percent fall in quarterly profit as the impact of a strong dollar on overseas revenue offset growing sales of its mainstay older drugs.

    7. Buoyed by Drug Sales, J & J Posts Steady 1Q, but Increasing Competition Should Slow Growth

      Commentary

      Tue, 14 Apr 2015

      Johnson & Johnson reported first-quarter results ..... Following the recent trend, J & J 's drug group once again ..... which represent 5% of J & J 's drug sales. The increasing ..... Imbruvica) will help mitigate J & J 's headwinds. We expect

    8. Caution: Slowing Growth Ahead for J & J

      Headlines

      Tue, 14 Apr 2015

      Johnson & Johnson JNJ reported first-quarter results ..... Following the recent trend, J & J 's drug group once again ..... which represent 5% of J & J 's drug sales. The increasing ..... Imbruvica) will help mitigate J & J 's headwinds. We expect

    9. Venture capitalists ride biotech wave one drug at a time

      Headlines

      Fri, 10 Apr 2015

      LONDON, April 10 (Reuters) - How many people does it take to run a successful biotech company? Just two, judging by the sale of XO1, a one-drug British firm snapped up last month by Johnson & Johnson .

    10. Morningstar's Dividend Playbook

      Video Reports

      Fri, 10 Apr 2015

      you expected. So, in the case of [TICKER: JNJ ] Johnson & Johnson ( JNJ ), on the lower-right-hand corner of the ..... important not overpay for a stock, like [TICKER: JNJ ] Johnson & Johnson . When you look at the market today, do you see

      JNJ found at 27:00, 28:01

      are going to earn less than you expected. So, in the case of [TICKER: JNJ ] Johnson & Johnson ( JNJ ), on the lower-right-hand corner of the screen, the dividend has, frankly, grown faster over the 10 years I've owned the stock than I initially expected. But because that dividend growth has slowed along with earnings growth slowing, the dividend yield has had to come up to compensate. That means the share price has gone up more slowly than the dividend rate. And today, [TICKER: JNJ ] Johnson & Johnson is more of a high-2%-yielding stock as opposed to less than 2% when I bought it. So, instead of,
      And this is the experience we've had from [TICKER:O] Realty Income (O), which, like [TICKER: JNJ ] Johnson & Johnson, is a core holding but one that has worked out much better for us and our strategy over the
    « Prev12345Next »
    Content Partners